NCT05104931View on ClinicalTrials.gov

PK Evaluation of a Nanoformed Oral IR Piroxicam Tablet in Healthy Subjects

PHASE1CompletedINTERVENTIONAL
Enrollment

12

Participants

Timeline

Start Date

December 2, 2020

Primary Completion Date

February 1, 2021

Study Completion Date

February 1, 2021

Conditions
Pain
Interventions
DRUG

Nanoformed Piroxicam IR Tablet

Orally delivered Nanoformed Piroxicam

DRUG

Felden (piroxicam) Tablets

orally delivered Felden (reference) tablets

DRUG

Brexidol (piroxicam) Tablets

orally delivered Brexidol (reference) tablets

Trial Locations (1)

NG11 6JS

Quotient Sciences, Nottingham

All Listed Sponsors
lead

Nanoform Finland Plc

INDUSTRY

NCT05104931 - PK Evaluation of a Nanoformed Oral IR Piroxicam Tablet in Healthy Subjects | Biotech Hunter | Biotech Hunter